Skip to main content




India's Serum Institute to boost production of COVID-19 vaccine doses to 200 million

BENGALURU: Serum Institute of India will make up to 200 million COVID-19 vaccine doses for poorer countries, including India, next year, as the Bill & Melinda Gates Foundation and GAVI vaccines alliance have doubled their funding, the company said on Tuesday (Sep 29). 

The extra funds will help Serum boost manufacturing of the vaccine candidates from AstraZeneca Plc and Novavax Inc, for delivery under the COVAX scheme as early as the first half of 2021.

READ: Global COVID-19 death toll passes 1 million

The collaboration takes forward an initial agreement signed in August by Serum, GAVI and the Gates Foundation for 100 million doses to be priced at a maximum of US$3 each.

The total funding provided is now US$300 million, and the expanded collaboration also has an option for the provision of additional doses as needed.

The so-called COVAX plan, co-led by the World Health Organization (WHO) and GAVI, aims to deliver 2 billion vaccine doses around the world by the end of 2021. More than 150 nations have joined the plan, though China and the United States have not signed up.

The global death toll from COVID-19 passed 1 million on Tuesday, according to a Reuters tally.

India, which leads the world in the daily average number of new infections reported, saw its coronavirus case tally rise to 6.15 million as of Tuesday.

BOOKMARK THIS: Our comprehensive coverage of the coronavirus outbreak and its developments

Download our app or subscribe to our Telegram channel for the latest updates on the coronavirus outbreak:

Source: Reuters


Also worth reading